This version has Isomorphic Labs far more in the focus of the press release, which seems to be now the commercial arm more or less licensing access out.

The new AlphaFold server does not do everything the paper says AlphaFold 3 says it does. You cannot predict docking with the server! That is the main interest of pharma companies, 'does our medication bind to the target protein?'. From the FAQ: 'AlphaFold Server is a web-service that offers customized biomolecular structure prediction. It makes several newer AlphaFold3 capabilities available, including support for a wider range of molecule type' - that's not ALL AlphaFold3 capabilities. Isomorphic prints the money with those additional capabilities.

It's hilarious that Google says they don't allow this for safety reasons, pure OpenAI fluff. It's just money.

I wonder what the license for RoseTTAFold is. On github you have:

https://github.com/RosettaCommons/RoseTTAFold/blob/main/LICE...

But there's also:

https://files.ipd.uw.edu/pub/RoseTTAFold/Rosetta-DL_LICENSE....

Which is it?

I don't think it was ever pure research. The article talks about infinity labs, which is the co. Mercial branch for drug discovery.

I do agree that Google seems bad at commercialization, which is why I'm curious on what the strategy is.

It is hard to see them being paid consultants or effective partners for pharma companies, let alone developing drugs themselves.